ARCHIVES

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

This article is from The Cancer Letter archive.

Vol. 30 No. 21 | May 21, 2004

Download PDF Visit The Full Archive

Related Articles

Nutrition RFP Canceled, Job Added To Existing Contract

April 4, 1975

Only 10% Of Breast Cancer Patients May Benefit From Contralateral Mastectomy

March 26, 2010

Breast Cancer Action Plan Committee Outrages By Plans for $14M In NCI Funds

August 1, 1997

FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes.

April 27, 2007

Cvitkovic Responds To Story On March ODAC Meeting.

June 23, 2000

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

August 28, 2009